image: Announcing Institute for Healthier Living Abu Dhabi
as Sponsor of ARDD 2025
Credit: Institute for Healthier Living Abu Dhabi
The University of Copenhagen is excited to announce the Institute for Healthier Living Abu Dhabi (IHLAD) as a sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online.
The Institute is the world’s first regulator-approved and licensed Healthy Longevity Medicine Center and will present its groundbreaking approach to advancing healthspan via a keynote and evidence-based strategic briefings during the Longevity Medicine Track on August 25 and 27. Dr. Bartlomiej Piechowski-Jozwiak, Head of Research at the Institute, will join leading international scientists in exploring the science and practice of precision geromedicine, emphasizing how regulatory innovation, translational research, and personalized proactive care can reshape the global approach to aging.
Redefining Healthy Longevity Medicine
The Institute was established to bridge the gap between cutting-edge aging research and real-world clinical application, with the purpose of helping people live longer and healthier lives. By focusing on the biologic process of aging, the Institute leverages advanced clinical care, precision diagnostics, lifestyle medicine, proven therapeutics, and research to improve healthspan. Three integrated pillars - the clinical application of Healthy Longevity Medicine, Population Health Research, and its Innovation Hub - create a continuous feedback loop that accelerates the translation of discovery into member benefit.
“The Institute’s mission is to redefine healthspan optimization - not just as a clinical goal, but as a regulated, evidence-based pathway to integrate novel diagnostics and therapeutics safely into healthcare systems,” stated Dr. Piechowski-Jozwiak. “Through co-authoring the world’s first clinical guidelines for longevity medicine and advancing regulatory frameworks, we are ensuring this field develops responsibly and with global relevance. Abu Dhabi’s visionary health strategy provides an unparalleled environment for such innovation, with lessons that can be applied globally.”
Recently, the Institute launched a state-of-the-art Innovation Hub, housing GMP and non-GMP capabilities to support a translational research ecosystem designed to power the next generation of real-world applications and insights in longevity science. The Innovation Hub supports advanced diagnostics, therapeutic development, and population-scale biomarker validation within a regulated, high-performance environment. It is equipped with multi-omics pipelines, AI/ML-driven molecular insight platforms, and cutting-edge 3D/4D live cell and organoid imaging, enabling innovators to move from discovery to deployment with unprecedented speed.
The Innovation Hub will be home to AD-Omics, a joint venture with Singleron Biotechnologies establishing a single-cell multi-omics laboratory and center of excellence to advance precision diagnostics and chronic disease research, with applications ranging from developing cell-based regenerative therapies for musculoskeletal degeneration to accelerating genetic risk screening for cardiovascular disease in high-prevalence populations.
The platform’s capabilities are already being applied to initiatives such as identifying novel biomarkers for early-stage Alzheimer’s detection, a critical focus given that Alzheimer’s currently affects around 4,300 people in the UAE, with projections suggesting nearly 30,000 could be living with the disease by 2030.
The Institute is actively pursuing collaborative opportunities across academia, research and industry partners to co-develop and clinically validate new solutions, creating an evidence base that underpins its innovative model of care. By combining world-class infrastructure, cutting-edge technologies, and collaborative partnerships, the Innovation Hub is positioned as a launchpad for transformative health innovations with regional and global impact.
The Institute’s collaborative approach continues to catalyze global partnerships in healthy longevity, demonstrating how science, policy, and practice can unite not only to extend healthy lifespans and reduce the economic burden of age-related diseases, but also to help people live healthier lives through care and research focused on healthy longevity, lifestyle, and performance for both individuals and populations
ARDD has grown to become the largest and most important conference in longevity biotechnology. Each year, ARDD brings together a unique mix of academic luminaries, biotech innovators, investors, top pharmaceutical executives, physicians, and related health care professionals to discuss the latest advancements in aging research and the event provides unique opportunities to connect with brilliant minds, fostering collaboration and showcasing groundbreaking research in the field.
“We are extremely honored to host Professors Meldal and Levitt at ARDD2025. Their Nobel prize winning discoveries have been instrumental for drug development and molecular design in part through modeling of proteins and molecules, and in part through the ability to easily create new molecules. It is therefore a great pleasure that they are joining our conference.” said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
“We are really excited for ARDD2025, especially with Nobel Laureates Morten Meldal and Michael Levitt joining us. Their groundbreaking contributions have had a lasting impact on drug discovery, and having them at the conference is sure to make it an unforgettable experience.” said Daniela Bakula, Ph.D., University of Copenhagen.
“For 12 years, the Aging Research and Drug Discovery (ARDD) forum grew in size and in quality. It became the world’s main platform for academia-pharma-startup-investor partnership and dialogue. In 2025, the conference will feature the Nobel laureates, pharmaceutical industry executives and healthcare delivery leaders. ARDD is a unique platform for advancing longevity biotechnology around the world.” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine.
“At ARDD we strive to highlight the cutting-edge research and clinical applications in a new discipline of healthy longevity medicine. Having Nobel laureates join and speak at the ARDD conference underscores the critical importance of grounding longevity science and medicine in evidence-based, scientifically rigorous approaches.” said Prof. Dr. Evelyne Bischof, the organizer of the Longevity Medicine Days.
Aging research has become a great platform for advancing drug discovery with blockbuster potential, with pharmaceutical leaders like Novartis, Biogen, and Eli Lilly actively supporting this transformative field. ARDD has established itself as the go-to venue where scientists and pharma companies collaborate, share insights, and launch aging-focused research initiatives. In 2024, industry leaders such as Eli Lilly, Novartis, Regeneron, Biogen, and Lundbeck presented their latest research at ARDD, highlighting the meeting's pivotal role in advancing healthspan and longevity science. Be part of ARDD 2025 and contribute to shaping the future of medicine.
For further information, images or interviews, please contact:
About Aging Research for Drug Discovery Conference
At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we will have a special day called Longevity Medicine Day, specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest to extend the healthy lifespan of everyone on the planet.